BALA CYNWYD, Pa. -- (Business Wire)
Law office of Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of DUSA Pharmaceuticals,
Inc. (“DUSA” or the “Company”) (Nasdaq: DUSA) relating to the proposed
acquisition by Sun Pharmaceutical Industries Ltd. (“Sun”).
Under the terms of the transaction, DUSA shareholders will receive only
$8.00 in cash for each share of DUSA stock they own. The investigation
concerns possible breaches of fiduciary duty and other violations of
state law by the Board of Directors of DUSA for not acting in the
Company’s shareholders' best interests in connection with the sale
process to Sun. The transaction may undervalue the Company and will not
result in any substantial gain for many DUSA shareholders as DUSA stock
traded at $7.00 on October 16, 2012. In addition, an analyst has set a
$9.50 per share price target for DUSA.
If you own shares of DUSA stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions, you
may e-mail or call the law office of Brodsky & Smith, LLC who will,
without obligation or cost to you, attempt to answer your questions. You
may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at
Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004,
by e-mail at email@example.com
by calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Source: Brodsky & Smith, LLC
© 2018 Canjex Publishing Ltd. All rights reserved.